SCHEMBL25259090

SCHEMBL25259090

N#Cc1ccc(-c2cc(F)ccc2O)c(C2CC2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.39
MAOA P21397 2/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.36
CHRNA1 P02708 1/20 0.36
CHRNG P07510 1/20 0.36
CHRNB1 P11230 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA4 P43681 1/20 0.36
CHRND Q07001 1/20 0.36
P4HB P07237 1/20 0.35
CYP11B2 P19099 1/20 0.35
ACLY P53396 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
ABCC9 O60706 1/20 0.35
RBP4 P02753 3/20 0.34
IDO1 P14902 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30591409 1.00 KDM1A (0.39) KDM1AMAOAPTGDR2CHRNA1CHRNG
SCHEMBL2456208 0.78 CHRNA1 (0.46) KDM1AMAOAPTGDR2CHRNA1CHRNG
SCHEMBL29519663 0.77 GABRG2 (0.43) KDM1ACHRNA1CHRNGCHRNB1CHRNB2
SCHEMBL28093094 0.77 CHRNA1 (0.45) KDM1AMAOAPTGDR2CHRNA1CHRNG
SCHEMBL30591162 0.73 NPC1 (0.38) CYP11B2IDO1NPC1
SCHEMBL2695090 0.72 CHRNA1 (0.46) PTGDR2CHRNA1CHRNGCHRNB1CHRNB2
SCHEMBL2049413 0.72 CHRNA1 (0.46) KDM1AMAOAPTGDR2CHRNA1CHRNG
SCHEMBL4878052 0.71 PTGDR2 (0.55) KDM1AMAOAPTGDR2CHRNA1CHRNG
SCHEMBL11615171 0.71 KDM1A (0.53) KDM1AMAOA
SCHEMBL1094923 0.69 CA3 (0.43) KDM1APTGDR2CHRNB2CHRNB4CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317748-A1 CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE BIONOVA PHARMACEUTICALS LTD. (KY) 2024-09-26 US disclosed
EP-4271676-A1 CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE Bionova Pharmaceuticals (Shanghai) Limited (CN) 2023-11-08 EP disclosed
WO-2023098876-A1 CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE BIONOVA PHARMACEUTICALS (SHANGHAI) LIMITED (CN) 2023-06-08 WO disclosed
WO-2023098876-A1 CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE BIONOVA PHARMACEUTICALS (SHANGHAI) LIMITED (CN) 2023-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317748-A1 CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE SDHA, PDHA1, GLS KDM1A 1042/4885MAOA 1859/4885PTGDR2 1793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.